VIDEO: High-dose risankizumab exhibits promising results for psoriasis in KNOCKOUT study

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into psoriasis from the American Academy of Dermatology Annual Meeting, examining results from the phase 2 KNOCKOUT study.

Chovatiya, clinical associate professor at Chicago Medical School at Rosalind Franklin University and assistant clinical professor at George Washington University School of Health Sciences, discussed the study, which examined whether moderate to severe plaque psoriasis could be effectively “cured” with a high upfront dose of the interleukin-23 blocker risankizumab (Skyrizi, AbbVie).

“This was really one of the earliest insights we have into this one way we can drive disease modification in psoriasis and actually have long-lasting results, potentially in the absence of therapy or following really good therapy,” Chovatiya said.